%0 Journal Article
%A Casanova, María José
%A Chaparro, María
%A Mínguez, Miguel
%A Ricart, Elena
%A Taxonera, Carlos
%A García-López, Santiago
%A Guardiola, Jordi
%A López-San Román, Antonio
%A Iglesias, Eva
%A Beltrán, Belén
%A Sicilia, Beatriz
%A Vera, María Isabel
%A Hinojosa, Joaquín
%A Riestra, Sabino
%A Domènech, Eugeni
%A Calvet, Xavier
%A Pérez-Calle, José Lázaro
%A Martín-Arranz, María Dolores
%A Aldeguer, Xavier
%A Rivero, Montserrat
%A Monfort, David
%A Barrio, Jesús
%A Esteve, María
%A Márquez, Lucía
%A Lorente, Rufo
%A García-Planella, Esther
%A de Castro, Luisa
%A Bermejo, Fernando
%A Merino, Olga
%A Rodríguez-Pérez, Antonio
%A Martínez-Montiel, Pilar
%A Van Domselaar, Manuel
%A Alcaín, Guillermo
%A Domínguez-Cajal, Manuel
%A Muñoz, Carmen
%A Gomollón, Fernando
%A Fernández-Salazar, Luis
%A García-Sepulcre, Mariana Fe
%A Rodríguez-Lago, Iago
%A Gutiérrez, Ana
%A Argüelles-Arias, Federico
%A Rodriguez, Cristina
%A Rodríguez, Gloria Esther
%A Bujanda, Luis
%A Llaó, Jordina
%A Varela, Pilar
%A Ramos, Laura
%A Huguet, José María
%A Almela, Pedro
%A Romero, Patricia
%A Navarro-Llavat, Mercè
%A Abad, Águeda
%A Ramírez-de la Piscina, Patricia
%A Lucendo, Alfredo J
%A Sesé, Eva
%A Madrigal, Rosa Eva
%A Charro, Mara
%A García-Herola, Antonio
%A Pajares, Ramón
%A Khorrami, Sam
%A Gisbert, Javier P
%T Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry.
%D 2020
%U http://hdl.handle.net/10668/14490
%X The effectiveness of the switch to another anti-tumor necrosis factor (anti-TNF) agent is not known. The aim of this study was to analyze the effectiveness and safety of treatment with a second and third anti-TNF drug after intolerance to or failure of a previous anti-TNF agent in inflammatory bowel disease (IBD) patients. We included patients diagnosed with IBD from the ENEIDA registry who received another anti-TNF after intolerance to or failure of a prior anti-TNF agent. A total of 1122 patients were included. In the short term, remission was achieved in 55% of the patients with the second anti-TNF. The incidence of loss of response was 19% per patient-year with the second anti-TNF. Combination therapy (hazard ratio [HR], 2.4; 95% confidence interval [CI], 1.8-3; P  Approximately half of the patients who received a second anti-TNF achieved remission; nevertheless, a significant proportion of them subsequently lost response. Combination therapy and type of IBD were associated with loss of response. Remission was achieved in almost 50% of patients who received a third anti-TNF; nevertheless, a significant proportion of them subsequently lost response.
%K Crohn’s disease
%K anti-TNF
%K inflammatory bowel disease
%K switch
%K ulcerative colitis
%~